Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
This investigation tested the mutation prevention concentration (MPC) concept using imipenem, meropenem, ceftriaxone, and ertapenem against three strains of Streptococcus pneumoniae (PCN MIC = 0.012, 1, 8 mg/L, respectively). MIC, MBC, and MPC values for each of the beta-lactams did not differ by more than one tube dilution. While an interesting concept, MPC may not apply to antimicrobials that do not utilize a dual targeting system, such as beta-lactams, or to bacteria that exhibit multiple mechanisms of resistance and/or mutate at a rate where the frequency would likely be captured by the standard inoculum size used in routine MIC testing.
College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Laurie B
LB
Hovde
Sarah E
SE
Rotschafer
Khalid H
KH
Ibrahim
Brent
B
Gunderson
Elizabeth D
ED
Hermsen
John C
JC
Rotschafer
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002443:Ceftriaxone / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D000077727:Ertapenem; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D007769:Lactams; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects*; D010597:Pharmacogenetics; D011336:Probability; D012680:Sensitivity and Specificity; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics; D013845:Thienamycins / Q000494:pharmacology*; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D013845:Thienamycins; D047090:beta-Lactams; D015378:Imipenem; D002443:Ceftriaxone; D000077731:Meropenem; D000077727:Ertapenem